ArticleIDCases2026
Case report: Maribavir as salvage therapy for multidrug-resistant CMV DNAemia in a non-transplant patient with ocular cicatricial pemphigoid.
Article in IDCases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytomegalovirus (CMV) is a significant cause of morbidity in immunocompromised patients, particularly those receiving chronic systemic therapy for autoimmune diseases such as ocular cicatricial pemphigoid (OCP). While the novel oral agent maribavir is approved for refractory CMV in post-transplant recipients, data regarding its efficacy in non-transplant populations remain scarce. We report the case of a 45-year-old female with OCP and comorbid Crohn's disease who developed multidrug resistant (MDR) CMV gastroenterocolitis. After failing sequential therapy with ganciclovir and foscarnet due to the emergence of UL97 (M460V/I) and UL54 (V781I) mutations, she achieved complete virological clearance with maribavir. This case highlights a novel, off-label application of maribavir in a non-transplant host with complex iatrogenic immunosuppression and sequential multidrug resistant CMV, demonstrating its role as a potent salvage therapy that avoids the nephrotoxicity associated with traditional agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.